The startup develops genetic medicines using a proprietary alpha anomeric-bicyclo DNA platform to precisely modulate RNA targets, specifically for neuromuscular diseases. This technology enhances treatment specificity and effectiveness while minimizing common side effects associated with existing oligonucleotide chemistries.
Funding
Funding not disclosed
Founders
Product
Problem
Many neuromuscular diseases lack effective treatments due to the challenges of delivering drugs to affected tissues and the difficulty in selectively modulating gene expression. Existing oligonucleotide therapies often suffer from off-target effects and limited cellular uptake, hindering their therapeutic potential.
Solution
This startup is developing a new class of genetic medicines based on a proprietary alpha anomeric-bicyclo DNA (α-anomeric-bNA) platform. This technology enables precise targeting and modulation of RNA, offering enhanced specificity and efficacy in treating neuromuscular diseases. The α-anomeric-bNA platform is designed to improve drug delivery, increase cellular uptake, and minimize off-target interactions, leading to more effective and safer therapies. By selectively modulating RNA targets, the company aims to address the underlying causes of neuromuscular diseases and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from various neuromuscular diseases, as well as pharmaceutical companies seeking novel therapeutic approaches in this area.
Features
- α-anomeric-bNA chemistry for enhanced RNA targeting specificity
- Improved cellular uptake and biodistribution compared to traditional oligonucleotides
- Reduced off-target effects and improved safety profile
- Customizable design for targeting a wide range of RNA sequences
- Potential for oral delivery and improved patient compliance